 Hallucinogens
"Hallucinogens" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs capable of inducing illusions, hallucinations, delusions, paranoid ideations, and other alterations of mood and thinking. Despite the name, the feature that distinguishes these agents from other classes of drugs is their capacity to induce states of altered perception, thought, and feeling that are not experienced otherwise.
| Descriptor ID |
D006213
|
| MeSH Number(s) |
D27.505.696.388 D27.505.954.427.300 D27.505.954.427.700.372
|
| Concept/Terms |
Hallucinogens- Hallucinogens
- Psychotomimetic Agents
- Agents, Psychotomimetic
- Hallucinogenic Agents
- Agents, Hallucinogenic
- Hallucinogenic Substances
- Substances, Hallucinogenic
- Psychedelics
- Psychedelic Agents
- Agents, Psychedelic
- Hallucinogenic Drugs
- Drugs, Hallucinogenic
|
Below are MeSH descriptors whose meaning is more general than "Hallucinogens".
Below are MeSH descriptors whose meaning is more specific than "Hallucinogens".
This graph shows the total number of publications written about "Hallucinogens" by people in UAMS Profiles by year, and whether "Hallucinogens" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2023 | 7 | 1 | 8 | | 2022 | 7 | 0 | 7 | | 2021 | 1 | 1 | 2 | | 2020 | 0 | 1 | 1 | | 2018 | 1 | 2 | 3 | | 2014 | 2 | 0 | 2 | | 2013 | 1 | 1 | 2 | | 2012 | 0 | 2 | 2 | | 2010 | 3 | 1 | 4 | | 2009 | 1 | 1 | 2 | | 2007 | 4 | 0 | 4 | | 2006 | 3 | 1 | 4 | | 2005 | 3 | 0 | 3 | | 2003 | 1 | 0 | 1 | | 1998 | 1 | 1 | 2 | | 1997 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Hallucinogens" by people in Profiles over the past ten years.
-
Cohen N, Mathew M, Brent J, Wax P, Davis AL, Obilom C, Burns MM, Canning J, Baumgartner K, Koons AL, Wiegand TJ, Judge B, Hoyte C, Chenoweth JA, Froberg B, Farrar H, Carey JL, Hendrickson RG, Hodgman M, Caravati EM, Christian MR, Wolk BJ, Seifert SA, Bentur Y, Levine M, Farrugia LA, Vearrier D, Minns AB, Kennedy JM, Kirschner RI, Aldy K, Schuh S, Campleman S, Li S, Myran DT, Feng L, Freedman SB, Finkelstein Y. Severe outcomes following pediatric cannabis intoxication: a prospective cohort study of an international toxicology surveillance registry. Clin Toxicol (Phila). 2023 08; 61(8):591-598.
-
Gannon BM, Fitzgerald LR, Godwin CO, Hughes-Meredith HD, Rice KC, Fantegrossi WE. Effects of ambient temperature on locomotor activity and place conditioning elicited by abused psychostimulants in mice: Role of 3,4-methylenedioxy moiety. Drug Alcohol Depend. 2023 09 01; 250:110917.
-
Haney M, Vall?e M, Fabre S, Collins Reed S, Zanese M, Campistron G, Arout CA, Foltin RW, Cooper ZD, Kearney-Ramos T, Metna M, Justinova Z, Schindler C, Hebert-Chatelain E, Bellocchio L, Cathala A, Bari A, Serrat R, Finlay DB, Caraci F, Redon B, Mart?n-Garc?a E, Busquets-Garcia A, Matias I, Levin FR, Felpin FX, Simon N, Cota D, Spampinato U, Maldonado R, Shaham Y, Glass M, Thomsen LL, Mengel H, Marsicano G, Monlezun S, Revest JM, Piazza PV. Signaling-specific inhibition of the CB1 receptor for cannabis use disorder: phase 1 and phase 2a randomized trials. Nat Med. 2023 Jun; 29(6):1487-1499.
-
Fujiwara R, Journey M, Al-Doori F, Bell P, Judge B, Miracle K, Ito K, Jones S. Potential neonatal toxicity of new psychoactive substances. Pharmacol Ther. 2023 08; 248:108468.
-
Shmulewitz D, Budney AJ, Borodovsky JT, Bujno JM, Walsh CA, Struble CA, Livne O, Habib MI, Aharonovich E, Hasin DS. Dimensionality and differential functioning of DSM-5 cannabis use disorder criteria in an online sample of adults with frequent cannabis use. J Psychiatr Res. 2023 Jul; 163:211-221.
-
Nigam K, Curseen KA, Beaussant Y. Psychedelics and Related Pharmacotherapies as Integrative Medicine for Older Adults in Palliative Care. Clin Geriatr Med. 2023 Aug; 39(3):423-436.
-
Graves JM, Dilley JA, Klein T, Liebelt E. Suspected Suicidal Cannabis Exposures Reported to US Poison Centers, 2009-2021. JAMA Netw Open. 2023 04 03; 6(4):e239044.
-
Hasin DS, Borodovsky J, Shmulewitz D, Walsh C, Struble CA, Livne O, Habib MI, Fink DS, Aharonovich E, Budney A. Adult use of highly-potent ?9-THC cannabis concentrate products by U.S. state cannabis legalization status, 2021. Addict Behav. 2023 05; 140:107617.
-
Klein TA, Dilley JA, Graves JM, Liebelt EL. Synthetic cannabinoid poisonings and access to the legal cannabis market: findings from US national poison centre data 2016-2019. Clin Toxicol (Phila). 2022 09; 60(9):1024-1028.
-
Livne O, Budney A, Borodovsky J, Walsh C, Shmulewitz D, Fink DS, Struble CA, Habib M, Aharonovich E, Hasin DS. Delta-8 THC use in US adults: Sociodemographic characteristics and correlates. Addict Behav. 2022 10; 133:107374.
-
Forsyth AD, Kulik MC, Richmond McKnight T, Perkins AD, Balla A. University of California Cannabis Research Workshop, May 2021: Meeting Summary. Cannabis Cannabinoid Res. 2022 04; 7(2):152-155.
-
Lazris D, Gaur D, Curseen K, Kavalieratos D, Maxwell M, Quest T, Zarrabi AJ. Integrated Medical Cannabis Consultations in a Palliative Care Program: Policies, Procedures, and Progress after Six Years of Practice. J Palliat Med. 2022 05; 25(5):802-806.
-
al'Absi M, DeAngelis B, Fiecas M, Budney A, Allen S. Effects of regular cannabis and nicotine use on acute stress responses: chronic nicotine, but not cannabis use, is associated with blunted adrenocortical and cardiovascular responses to stress. Psychopharmacology (Berl). 2022 May; 239(5):1551-1561.
-
Kelleghan AR, Sofis MJ, Budney A, Ceasar R, Leventhal AM. Associations of cannabis product source and subsequent cannabis use among adolescents. Drug Alcohol Depend. 2022 04 01; 233:109374.
-
Connor JP, Stjepanovic D, Budney AJ, Le Foll B, Hall WD. Clinical management of cannabis withdrawal. Addiction. 2022 07; 117(7):2075-2095.
-
Hasin DS, Borodovsky J, Shmulewitz D, Walsh C, Livne O, Struble CA, Aharonovich E, Fink DS, Budney A. Use of highly-potent cannabis concentrate products: More common in U.S. states with recreational or medical cannabis laws. Drug Alcohol Depend. 2021 12 01; 229(Pt B):109159.
-
Berquist MD, Fantegrossi WE. Effects of 5-HT2A receptor agonist 2,5-dimethoxy-4-iodoamphetamine on alcohol consumption in Long-Evans rats. Behav Pharmacol. 2021 08 01; 32(5):382-391.
-
Borodovsky JT, Sofis MJ, Grucza RA, Budney AJ. The importance of psychology for shaping legal cannabis regulation. Exp Clin Psychopharmacol. 2021 Feb; 29(1):99-115.
-
Wall MM, Liu J, Hasin DS, Blanco C, Olfson M. Use of marijuana exclusively for medical purposes. Drug Alcohol Depend. 2019 02 01; 195:13-15.
-
Timko C, Cucciare MA. Commentary on Socias et al. (2018): Clinical research perspectives on cannabis use in opioid agonist treatment. Addiction. 2018 12; 113(12):2259-2260.
-
Timko C, Han X, Woodhead E, Shelley A, Cucciare MA. Polysubstance Use by Stimulant Users: Health Outcomes Over Three Years. J Stud Alcohol Drugs. 2018 09; 79(5):799-807.
-
Smith DA, Bailey JM, Williams D, Fantegrossi WE. Tolerance and cross-tolerance to head twitch behavior elicited by phenethylamine- and tryptamine-derived hallucinogens in mice. J Pharmacol Exp Ther. 2014 Dec; 351(3):485-91.
-
Fantegrossi WE, Gray BW, Bailey JM, Smith DA, Hansen M, Kristensen JL. Hallucinogen-like effects of 2-([2-(4-cyano-2,5-dimethoxyphenyl) ethylamino]methyl)phenol (25CN-NBOH), a novel N-benzylphenethylamine with 100-fold selectivity for 5-HT2A receptors, in mice. Psychopharmacology (Berl). 2015 Mar; 232(6):1039-47.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|